Skip to main content

Table 1 Properties of featured novel agents and treatment combinations in AML from ASH 2022

From: Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting

Drug

Regimen Backbone

Indication

Mechanism

References

Magrolimab

AZA/VEN

ND AML

Anti-CD47 antibody

[6]

Gilteritinib

AZA/VEN

ND and R/R AML

FLT3 inhibitor

[7]

SNDX-5613 (Revumenib)

N/A

R/R AML

Menin inhibitor

[3]

KO-539 (Ziftomenib)

N/A

R/R AML

Menin inhibitor

[4]

Pivekimab sunirine (PVEK)

AZA/VEN

R/R AML

Antibody–drug conjugate targeting CD123

[5]

  1. AZA azacitidine, VEN venetoclax, ND newly diagnosed, R/R relapsed/refractory